Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Led by a management team with deep expertise and a proven track record, Ascletis focuses on three therapeutic areas with unmet medical needs from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. Through excellent execution, Ascletis rapidly advances its drug pipeline with an aim of leading in global competition. 

To date, Ascletis has multiple drug candidates in its R&D pipeline. The most advanced drug candidates include ASC22 (CHB functional cure), ASC40 (acne), ASC40 (recurrent glioblastoma), ASC40 (NASH), ASC41 (NASH) and ASC61 (advanced solid tumors).

Our manufacturing facility located in Shaoxing, Zhejiang province with a total gross floor area of 17,000 square meters. This facility consists of API and formulation production lines, with a designed annual production capacity of 130 million tablets. We have obtained the drug production license for our manufacturing facility and passed GMP inspections by NMPA.

We believe that our integrated platform led by our experienced senior management team will expand our business and deliver sustainable growth in the future. Our platform has enabled us to become a partner-of-choice in China for global leading pharmaceutical companies, as demonstrated by the R&D and commercial collaborations with global pharmaceutical companies such as Roche.